FDA revises Lilly’s COVID-19 antibody combo EUA for use after exposure to virus By Reuters
(Reuters) – The U.S. Food and Drug Administration said on Thursday it has revised its emergency use authorization for Eli Lilly (NYSE:)’s COVID-19 antibody cocktail to include for use after exposure to the virus in patients who are at high risk for progression to severe disease.
Bamlanivimab or etesevimab is approved for people aged 12 and over who have mild to moderate infection. They are also at risk of developing severe COVID-19.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.